Merit医疗系统 MMSI 深 沪
已收盘 12-26 16:00:00 美东时间
87.39
0.000
0.00%
华盛通- 最 高87.57
- 今 开87.21
- 成交量 15.65万股
- 最 低 86.865
- 昨 收 87.39
- 总市值 51.75亿
- 52周最高 111.45
- 市盈率 静 43.10
- 换手率 0.26%
- 52周最低 78.116
- 委 比 87.25%
- 总股本 5921.91万
- 历史最高 111.45
- 量 比 0.26
- 振 幅 0.81%
- 历史最低 9.15
- 每 手 1
- 风险率 7.93%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Merit Medical to Participate at the J.P. Morgan Healthcare Conference
Merit Medical Systems, Inc. announced that its management will participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, January 12-15, 2026. Martha G. Aronson, CEO, and Raul Parra, CFO, will present a company overview on January 13 at 4:30 PM PT / 7:30 PM ET. Presentation materials and a live audio webcast will be available on Merit’s investor relations website, with a replay accessible for 90 days.
12-23 14:00
美股大行评级 | 德银首予Coinbase"买入"评级，目标价340美元；AERO获多家机构首予超配评级；大摩维持苹果"超配"评级，目标价升至315美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从9美元升至10美元；摩根大通：上调Recursion Pharmaceuticals评级至"超配"，目标价从10美元升至11美元
12-18 10:54
Is the Market Bullish or Bearish on Merit Medical Systems Inc?
Merit Medical Systems Inc's (NYSE:MMSI) short interest as a percent of float ha...
12-12 21:00
美股大行评级 | 花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级
花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级>>
11-17 10:49
Barrington Research Maintains Outperform on Merit Medical Systems, Maintains $106 Price Target
Barrington Research analyst Michael Petusky maintains Merit Medical Systems (NASDAQ:MMSI) with a Outperform and maintains $106 price target.
11-15 04:29
Merit Medical Systems Begins WRAPSODY CIE Commercialization
An announcement from Merit Medical Systems ( ($MMSI) ) is now available. Merit ...
11-14 06:51
Merit Medical Provides Update on U.S. Reimbursement and Commercial Strategies for WRAPSODY® Cell-Impermeable Endoprosthesis
Merit Medical Systems announced that the U.S. CMS has deferred its application for transitional pass-through incremental payment for WRAPSODY® CIE procedures until 2027. CEO Martha Aronson stated that while disappointed, this presents an opportunity for a strategic pivot, focusing on patient access, adoption, and utilization of their technology. WRAPSODY® CIE received FDA and Health Canada approval in 2024 and 2025, respectively, and is available...
11-13 21:05
美股大行评级 | 苹果、亚马逊、Cloudflare、西部数据、Twilio等获十多家机构集体上调目标价；杰富瑞首予Cloudflare"持有"评级，目标价250美元
今日重点评级关注：康托·菲茨杰拉德：维持Cabaletta Bio"超配"评级，目标价从15美元升至30美元；HC Wainwright & Co.：维持Invivyd"买入"评级，目标价从5美元升至10美元
11-03 20:20
Where Merit Medical Systems Stands With Analysts
In the latest quarter, 4 analysts provided ratings for Merit Medical Systems (N...
10-31 19:44
Merit Medical Systems shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY25 guidance above estimates.
Merit Medical Systems shares are trading higher after the company reported bett...
10-31 04:39
